Biologics have transformed the treatment of patients with type 2 (T2)-inflammation driven severe asthma (1). In appropriately selected patients, biologic use reduces asthma exacerbations and reliance on maintenance oral steroids (mOCS) and improves lung function and quality of life. The decision to initiate a biologic is usually led by specialist multi-disciplinary teams (MDTs).

中文翻译：

---

重症哮喘中的生物制剂——哪一种，何时何地？

生物制剂已经改变了 2 型 (T2) 炎症驱动的重度哮喘患者的治疗方法 (1)。In appropriately selected patients, biologic use reduces asthma exacerbations and reliance on maintenance oral steroids (mOCS) and improves lung function and quality of life. 启动生物制剂的决定通常由专业的多学科团队 (MDT) 领导。